For the Inventor, By the Inventor

Enter assignee name

Research Triangle Park, NC, United States of America

Burroughs Wellcome Co.

Calculating rank

USPTO Granted Patents = 521

Trademarks = 20

Forward Citations = 6,749

Loading Chart...

Loading Chart...

358 inventors (with patents filed for the assignee):

Kenneth W Bair (45 out of 45 patents)

Thomas A Krenitsky (27 out of 40 patents)

Janet L Rideout (23 out of 63 patents)

4. John Frederick Batchelor (19 out of 19 patents)

5. Harold Francis Hodson (15 out of 34 patents)

6. Susan Mary Daluge (15 out of 46 patents)

7. Samuel Wilkinson (15 out of 16 patents)

8. Robert W Morrison, Jr (14 out of 14 patents)

9. Virgil L Styles (14 out of 16 patents)

10. Sandra N Lehrman (14 out of 18 patents)

11. Phillip A Furman (13 out of 16 patents)

12. David Walter Barry (13 out of 25 patents)

13. William R Mallory (12 out of 12 patents)

14. Martha H St Clair (12 out of 16 patents)

15. Lawrence Edward Brieaddy (11 out of 17 patents)

Core Competencies:

Pharmaceutical Composition

Antiviral Agents

Therapeutic Nucleosides

Immunoglobulins

Chimeric Antibody

Indole Derivatives

Fusogenic Liposomes

Neuromuscular Blocking Agents

Anti-Atherosclerotic Compounds

Antigenic Preparations

Pharmacologically Active Compounds

Pesticidal Compositions

521 patents: Sort by Forward Citations

1. 7098006 - Chimeric antibody, pharmaceutical composition and process of its production (2006-08-29),

2. 5985318 - Fusogenic liposomes that are free of active neuraminidase (1999-11-16),

3. 5654403 - Immunoglobulins stabilized with a chelator of copper ions (1997-08-05),

4. 5644036 - Purified immunoglobulin (1997-07-01),

5. 5597708 - Cloning of a malarial gene (1997-01-28),

6. D376847 - Pharmaceutical tablet (1996-12-24),

7. 5547976 - Further indole derivatives with antiviral activity (1996-08-20),

8. 5547664 - Expression of recombinant proteins in attenuated bacteria (1996-08-20),

9. 5545405 - Method for treating a mammal suffering from cancer with a (1996-08-13),

10. 5545404 - Method for treating a mammal suffering from a T-cell medicated disorder (1996-08-13),

11. 5545403 - Method for treating a mammal by administering a CHO-glycosylated antibody (1996-08-13),

12. 5534535 - Therapeutic nucleosides (1996-07-09),

13. 5512269 - Method of treating retained pulmonary secretions (1996-04-30),

14. 5508310 - Immunopotentiatory agents and physiologically acceptable salts thereof (1996-04-16),

15. 5495944 - Bottle with tamper evident wrapping (1996-03-05),

Company Overview

Burroughs Wellcome Co., based in Research Triangle Park, NC, specializes in the development and manufacturing of pharmaceutical compositions. The company focuses on innovative therapeutic solutions, particularly in the fields of antiviral agents, therapeutic nucleosides, and immunoglobulins. Its research encompasses advanced technologies such as chimeric antibodies, indole derivatives, and fusogenic liposomes, contributing significantly to the pharmaceutical landscape and enhancing treatment options for various medical conditions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

521 Patents

#1 in Research Triangle Park, NC

#32 in North Carolina

#943 in US

#1,875 in the World

Research Triangle Park, NC, United States of America

Burroughs Wellcome Co.

Forward Citations = 6,749

358 inventors:

Kenneth W Bair (45 out of 45 patents)

Thomas A Krenitsky (27 out of 40 patents)

Janet L Rideout (23 out of 63 patents)

4. John Frederick Batchelor (19 out of 19 patents)

5. Harold Francis Hodson (15 out of 34 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Burroughs Wellcome Co.. Retrieved from https://idiyas.com/company/burroughs-wellcome-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…